Advancing Peptide-Based Vaccines Against Candida: A Comparative Perspective on Liposomal and Synthetic Formulations

The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of fungi (Basel) Ročník 11; číslo 10; s. 715
Hlavní autor: Xin, Hong
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 02.10.2025
Témata:
5-Methyltetrahydrofolate-homocysteine S-methyltransferase
Adjuvants
Animal models
Antibodies
Antifungal agents
antifungal immunotherapy
Antigen presentation
Antigens
Candida auris
Cobalt
CoPoP liposomes
Cytokines
Drug dosages
Drug resistance
Fructose
Fungal infections
Immunogenicity
Immunology
Licenses
Lymphocytes
Lymphocytes T
Medical prognosis
Methionine
Multidrug resistance
Pathogens
peptide vaccine
Peptides
SNAP platform
Tropical diseases
Vaccination
Vaccines
Candida auris
antifungal immunotherapy
SNAP platform
CoPoP liposomes
peptide vaccine
ISSN:2309-608X, 2309-608X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform’s compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.
AbstractList The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform's compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform's compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.
The growing threat of multidrug-resistant fungal pathogens, especially , has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform's compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.
The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform’s compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.
Audience Academic
Author Xin, Hong
Author_xml – sequence: 1
  givenname: Hong
  surname: Xin
  fullname: Xin, Hong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41149905$$D View this record in MEDLINE/PubMed
BookMark eNptkt1rFDEUxQep2Fr75LsEfBFkaj5nJr6Ni9XCgoIf-DbcSe6sWWaSaTJb6H9vtltrFclDLpffOSeX3KfFkQ8ei-I5o-dCaPpmGwbGGKU1U4-KEy6oLiva_Dh6UB8XZyltKaVMNZXW4klxLBmTWlN1UqTWXoM3zm_IZ5wXZ7F8Bwkt-Q4mdzGRdgPOp4WswFtn4S1pySpMM0RY3DVmVUwzmts6eLJ2c0hhgpFknHy58ctPXJwhFyFOuzFLgk_PiscDjAnP7u7T4tvF-6-rj-X604fLVbsujZT1UgqwnFlVWY5DXxs-CME0qspoyhvRG2iEqGuruLUwNEaISpk8IjaoqFRDL06Ly4OvDbDt5ugmiDddANfdNkLcdBDz40bskEuOdV8NWSxrazT2NTMNlRZ436POXq8OXnMMVztMSze5ZHAcwWPYpU7wqpKSc8oy-vIfdBt20edJ95TSTOim-kNtIOc7P4Qlgtmbdm1TcamYFPvY8_9Q-VicnMmrMLjc_0vw4i58109o76f-_eMZeH0ATAwpRRzuEUa7_Up1D1ZK_ALaA7vc
Cites_doi 10.1128/msphere.00189-24
10.1099/jmm.0.045054-0
10.1016/j.vaccine.2021.06.001
10.1093/cid/ciw691
10.1126/scitranslmed.3004404
10.1016/j.ijid.2023.11.004
10.1073/pnas.0803195105
10.1128/JCM.02018-07
10.1128/msphere.00584-22
10.3390/pathogens11091035
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOA
DOI 10.3390/jof11100715
DatabaseName CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
CrossRef


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Botany
EISSN 2309-608X
ExternalDocumentID oai_doaj_org_article_e242e7b6f8e547dc9eb71c804da2bbe9
A862451439
41149905
10_3390_jof11100715
Genre Comment
Journal Article
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R21 AI168929
– fundername: NIH HHS
  grantid: R21AI168929
– fundername: NIAID NIH HHS
  grantid: R41 AI184019
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ACUHS
ADBBV
AFFHD
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
GROUPED_DOAJ
HCIFZ
HYE
IAO
ITC
KQ8
LK8
M7P
MODMG
M~E
OK1
OZF
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
RPM
NPM
ABUWG
AZQEC
COVID
DWQXO
GNUQQ
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c447t-3ad21d56d2efb7c2f3319e56c90283bca83377d52ddaf8c3365c158e8e5045fb3
IEDL.DBID M7P
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001603747500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2309-608X
IngestDate Mon Nov 03 22:05:43 EST 2025
Wed Oct 29 17:08:12 EDT 2025
Tue Oct 28 21:17:36 EDT 2025
Wed Nov 12 17:02:09 EST 2025
Tue Nov 11 03:50:41 EST 2025
Sat Nov 01 14:17:13 EDT 2025
Sat Nov 29 07:22:57 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Candida auris
antifungal immunotherapy
SNAP platform
CoPoP liposomes
peptide vaccine
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c447t-3ad21d56d2efb7c2f3319e56c90283bca83377d52ddaf8c3365c158e8e5045fb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
OpenAccessLink https://www.proquest.com/docview/3265913986?pq-origsite=%requestingapplication%
PMID 41149905
PQID 3265913986
PQPubID 2059559
ParticipantIDs doaj_primary_oai_doaj_org_article_e242e7b6f8e547dc9eb71c804da2bbe9
proquest_miscellaneous_3266442201
proquest_journals_3265913986
gale_infotracmisc_A862451439
gale_infotracacademiconefile_A862451439
pubmed_primary_41149905
crossref_primary_10_3390_jof11100715
PublicationCentury 2000
PublicationDate 2025-10-02
PublicationDateYYYYMMDD 2025-10-02
PublicationDate_xml – month: 10
  year: 2025
  text: 2025-10-02
  day: 02
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Journal of fungi (Basel)
PublicationTitleAlternate J Fungi (Basel)
PublicationYear 2025
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Xin (ref_6) 2008; 105
Lovell (ref_11) 2024; 138
Clancy (ref_7) 2008; 46
Huang (ref_1) 2024; 9
Sardi (ref_9) 2013; 62
Adams (ref_5) 2021; 39
ref_10
Brown (ref_2) 2012; 4
Lockhart (ref_3) 2017; 64
ref_4
Xin (ref_8) 2023; 8
References_xml – volume: 9
  start-page: e0018924
  year: 2024
  ident: ref_1
  article-title: Liposomal Fba and Met6 peptide vaccination protects mice from disseminated candidiasis
  publication-title: mSphere
  doi: 10.1128/msphere.00189-24
– volume: 62
  start-page: 10
  year: 2013
  ident: ref_9
  article-title: Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options
  publication-title: J. Med. Microbiol.
  doi: 10.1099/jmm.0.045054-0
– ident: ref_4
– volume: 39
  start-page: 4099
  year: 2021
  ident: ref_5
  article-title: Synthetic conjugate peptide Fba-Met6 (MP12) induces complement-mediated resistance against disseminated Candida albicans
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.06.001
– volume: 64
  start-page: 134
  year: 2017
  ident: ref_3
  article-title: Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciw691
– volume: 4
  start-page: 165rv113
  year: 2012
  ident: ref_2
  article-title: Hidden killers: Human fungal infections
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3004404
– volume: 138
  start-page: 73
  year: 2024
  ident: ref_11
  article-title: One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
  publication-title: Int. J. Infect. Dis.
  doi: 10.1016/j.ijid.2023.11.004
– volume: 105
  start-page: 13526
  year: 2008
  ident: ref_6
  article-title: Synthetic glycopeptide vaccines combining b-mannan and peptide epitopes induce protection against candidiasis
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0803195105
– volume: 46
  start-page: 1647
  year: 2008
  ident: ref_7
  article-title: Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.02018-07
– volume: 8
  start-page: e0058422
  year: 2023
  ident: ref_8
  article-title: Novel Intravenous Immunoglobulin Therapy for the Prevention and Treatment of Candida auris and Candida albicans Disseminated Candidiasis
  publication-title: mSphere
  doi: 10.1128/msphere.00584-22
– ident: ref_10
  doi: 10.3390/pathogens11091035
SSID ssj0001586993
Score 2.3049126
Snippet The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This...
The growing threat of multidrug-resistant fungal pathogens, especially , has underscored the need for effective antifungal vaccines. This commentary highlights...
SourceID doaj
proquest
gale
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 715
SubjectTerms 5-Methyltetrahydrofolate-homocysteine S-methyltransferase
Adjuvants
Animal models
Antibodies
Antifungal agents
antifungal immunotherapy
Antigen presentation
Antigens
Candida auris
Cobalt
CoPoP liposomes
Cytokines
Drug dosages
Drug resistance
Fructose
Fungal infections
Immunogenicity
Immunology
Licenses
Lymphocytes
Lymphocytes T
Medical prognosis
Methionine
Multidrug resistance
Pathogens
peptide vaccine
Peptides
SNAP platform
Tropical diseases
Vaccination
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9xADBYl5NBLaZo-3KRlCoGeTGKP5-HcdpcuOYSw0DbkNsyzpFA7rJ1C_n0k29ls2kMvvXpkj0caWZ_w6BPAUWV9fVIFkdsiSExQHLqUEylPtdUWv8m1GLo1XJ6riwt9dVWvtlp90ZmwkR54VNxxxBgSlZNJR1Gp4OvoVOE1Pt-WzsWhdO9E1VvJ1FgfrCVG3rEgj2Nef_yzTQXRoylqgLsVggam_r-_x3-gzCHaLF_Ciwkmstn4envwLDavYHfeIpS724du6IXsMeqwFZ1KCTGfYzQK7NJ6-lHesdkPzPi7ni2oaiXYUzZji0eeb7Z6LLFkbcPOr2_arv2FE6I4-3rXICrEidkSAe3U3qt7Dd-XX74tzvKpe0Luq0r1ObehLIKQoYzJKV8mjt4WhfTE18Kdt5pzpYIoQ7BJe86l8Ki2iHpGmJccfwM7TdvEd8BsoEZVEpMz4uIJGu2aUo3TFKGyWoYMjh4Uam5GkgyDyQXp3WzpPYM5KXsjQszWwwW0t5nsbf5l7ww-k6kM-V-_tt5OZQT4psRkZWZU8UIoECUPn0ii3_inww_GNpPfdgbBrCCiVC0z-LQZpjvpLFoT29tBBkFkicgpg7fjJtksqcL0EuO7eP8_lnoAz0vqNkzHFcpD2OnXt_ED7Prf_XW3_jhs-HsCywZN
  priority: 102
  providerName: Directory of Open Access Journals
Title Advancing Peptide-Based Vaccines Against Candida: A Comparative Perspective on Liposomal and Synthetic Formulations
URI https://www.ncbi.nlm.nih.gov/pubmed/41149905
https://www.proquest.com/docview/3265913986
https://www.proquest.com/docview/3266442201
https://doaj.org/article/e242e7b6f8e547dc9eb71c804da2bbe9
Volume 11
WOSCitedRecordID wos001603747500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2309-608X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586993
  issn: 2309-608X
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2309-608X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586993
  issn: 2309-608X
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2309-608X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586993
  issn: 2309-608X
  databaseCode: M7P
  dateStart: 20150601
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2309-608X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586993
  issn: 2309-608X
  databaseCode: BENPR
  dateStart: 20150601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2309-608X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586993
  issn: 2309-608X
  databaseCode: PIMPY
  dateStart: 20150601
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9swDCbWx2GXrnvWWxtoQIGdjM4PWfIuQxIk2IAuMPYospMh61FkQO00Tgf0st8-UnGSdgN22SWHiImUkJQ-yuRHgNNU6fxtanioIpNhgFKhS1XchS5XUuGenHPfreHiXEwmcjrNi-7Cre3SKtd7ot-oTaPpjvwMYQYnCkuZvZ9fh9Q1ip6udi00dmCPWBJin7pXbO9YuMzw_F2V5SUY3Z_9aFxEJGmC2uDeOYg8X__fu_IfWNOfOeNH_7vaQzjo0Cbrr8zjMTyw9RPYHzSICG-fQutbKms8vFhByS3GhgM81Ay7UJqet7esf6lmiB_ZkIpfjHrH-my4pQtnxbZSkzU1O5_Nm7a5wglRnH25rRFc4sRsjLi46xLWPoNv49HX4Yewa8IQ6jQVyzBRJo4Mz0xsXSV07BJ0WsszTbQvSaWVTBIhDI-NUU7qJMm4xv_dSssRLboqeQ67dVPbI2DKUL-rDGM8ovQxEs3DuRyniUyqZGYCOF1rpJyvuDZKjFFIceUdxQUwIG1tRIgg27_RLC7Lzt9Ki9DDiipzuI5UGJ3bSkRaolmquKpsHsAb0nVJbrxcKK26agRcKRFilX0qnCEwiZLH9yTR_fT94bUFlJ37t-VW_QG83gzTJymlrbbNjZdBLBojAAvgxcrKNj8pxSgVYQJ_-e8vfwUPY2pHTPkM8THsLhc39gT29c_lrF30YEdMZQ_2BqNJ8bnnLxt63j_o9dcIR4qPn4rvvwG2GhmL
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9NAEB2VtBJc-IYaCixSESer9dprr5EQSgJRo6ZRJErVnsx6d12lEnaIU1D-FL-RGX8kLUjceuAab7x28mbmjT0zD2A3UDreD4xwlWdCTFBSNKlUZG4WK6nQJ8eiUms4GUXjsTw9jScb8KvthaGyytYnVo7aFJqeke8hzRA0wlKGH2bfXVKNorerrYRGDYtDu_yJKVv5fvgR_983nA8-HfcP3EZVwNVBEC1cXxnuGREabrM00jzzEYVWhJrmmPipVtL3o8gIbozKpPb9UGhPSCutQPqTpT6e9xZsBgT2DmxOhkeTs_VTHSFDjPh1I6Dvx_t7F0Xm0Vi2iIR3r4S-SiHg7zjwB7utotzg3v_2-9yHuw2fZt3aAB7Ahs0fwlavQM67fARlJRqtMTyzCZXvGOv2MGwbdqI0VRSUrHuupsiQWZ_ae4x6x7qsvx6IzibrXlRW5Gw0nRVl8Q03xOXs8zJH-owbswEy_0YHrXwMX27khp9AJy9yuw1MGVL0CjGLpaFFRqIBZFmM23gmUDI0Duy2CEhm9TSRBLMwAkpyBSgO9AgdqyU0Arz6oJifJ41HSSySKxulYYbXEURGxzaNPC3R8BRPUxs78JawlZCjWsyVVk2_BV4pjfxKutQaRHQZV-5cW4kORl8_3CIuaRxcmazh5sDr1WH6JhXt5ba4rNYg2-ZIMR14WqN6dUsB5uFIhMSzf5_8Fdw-OD4aJaPh-PA53OEkvkzVG3wHOov5pX0BW_rHYlrOXzaWyODrTYP7N_p5cfQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9NAEB2VtEJc-IYGCixSEScr9dprr5EQSlIioobIElC1J7PejyqVsEOcgvLX-HXMOE7SgsStB67xxmsnb2be2DPzAPZDpZOD0AhP-SbCBCVHk8qF81yipEKfnIhareF4FI_H8uQkSbfg16oXhsoqVz6xdtSm1PSMvIM0Q9AISxl1XFMWkR4O3k2_e6QgRW9aV3IaS4gc2cVPTN-qt8ND_K9fcT54_7n_wWsUBjwdhvHcC5ThvhGR4dblseYuQERaEWmaaRLkWskgiGMjuDHKSR0EkdC-kFZagVTI5QGe9wZsIyUPeQu20-HH9HTzhEfICKP_sikwCJKDznnpfBrRFpMI76UwWKsF_B0T_mC6dcQb3Pmff6u7cLvh2ay7NIx7sGWL-7DTK5ELLx5AVYtJawzbLKWyHmO9HoZzw46VpkqDinXP1ASZM-tT249Rb1iX9TeD0lm66VFlZcFGk2lZld9wQ1zOPi0KpNW4MRtgRtDoo1UP4cu13PAjaBVlYXeBKUNKXxFmtzTMyEg0DOcS3MY3oZKRacP-Cg3ZdDllJMPsjECTXQJNG3qElPUSGg1ef1DOzrLG02QWSZeN88jhdYSx0YnNY19LNEjF89wmbXhNOMvIgc1nSqumDwOvlEaBZV1qGSIajSv3rqxEx6OvHl6hL2scX5VtoNeGl-vD9E0q5itseVGvQRbOkXq24fES4etbCjE_R4Iknvz75C_gJiI6Gw3HR0_hFidNZirq4HvQms8u7DPY0T_mk2r2vDFKBl-vG9u_ASV2erQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advancing+Peptide-Based+Vaccines+Against+Candida%3A+A+Comparative+Perspective+on+Liposomal+and+Synthetic+Formulations&rft.jtitle=Journal+of+fungi+%28Basel%29&rft.au=Xin%2C+Hong&rft.date=2025-10-02&rft.issn=2309-608X&rft.eissn=2309-608X&rft.volume=11&rft.issue=10&rft_id=info:doi/10.3390%2Fjof11100715&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2309-608X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2309-608X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2309-608X&client=summon